Posts Tagged ‘GSK1363089’:

A Comparison of the pharmacokinetics of foretinib free base tablet formulation to bisphosphate salt capsule formulation for solid tumors.

Naing A, Kurzrock R, Adams LM, Kleha JF, Laubscher KH, Bonate PL, Weller S, Fitzgerald C, Xu Y, Lorusso PM. “Invest New Drugs. 2010 Sep” Purpose: This phase I, open-label, randomized, 2-part crossover research assessed the security, pharmacokinetics and relative bioavailability of single doses of the anticancer Met inhibitor foretinib (previously known as GSK1363089, EXEL-2880

(Read More…)

VEGF and c-Met drives tumor invasion and metastasis in pancreatic islet cancer.

You WK, Sennino B, Williamson CW, Falc√≥n B, Hashizume H, Yao LC, Aftab DT, McDonald DM. “Cancer Res. 2011 Jul” Angiogenesis inhibitors that block VEGF receptor (VEGFR) signaling sluggish the growth of numerous kinds of tumors, but ultimately the disease progresses. Many techniques are becoming explored to improve efficacy by concurrent inhibition of other functionally

(Read More…)

© Apoptosis|apoptosis inhibitor|apoptosis pathway